Targeting– tag –
-
Tempest Therapeutics Licenses Senlang’s In Vivo CAR-T Platform, Targeting Relapsed/Refractory Multiple Myeloma with Dual BCMA/GPRC5D Approach in Phase I Trial
AllSci USA Overview Tempest Therapeutics has secured an exclusive license option for Hebei Senlang Biotechnology's CD7-targeting lentiviral in vivo CAR-T platform and related product candidates. This platform generates CAR-T and CAR-NK c... -
CRISPR Gene Editing: Engineering Durable Cures for Congenital Diseases through Stem Cell and Liver Targeting
Liv Hospital Turkey Overview CRISPR gene editing technology promises a revolutionary approach to fundamentally cure congenital diseases by precisely correcting underlying genetic errors. By targeting the liver and hematopoietic stem cell... -
Single-Dose CRISPR Therapy Slashes LDL Cholesterol by 52.5%, Triglycerides by 47.8% in Landmark Phase 1 Trial
Medical Xpress USA Overview Vertex Pharmaceuticals' VERVE-101, a one-time CRISPR-Cas9 gene editing therapy, has achieved significant results in a Phase 1 trial, safely reducing LDL cholesterol by 52.5% and triglycerides by 47.8% in patie... -
T-MAXIMUM Allogeneic CAR T-Therapy MT027 Receives FDA Fast Track Designation for Recurrent Glioblastoma
PR Newswire USA Overview T-MAXIMUM PHARMACEUTICAL announced that its B7-H3-targeted allogeneic CAR T-cell therapy, MT027, has received Fast Track Designation (FTD) from the U.S. FDA for the treatment of recurrent glioblastoma. MT027 had ... -
Fate Therapeutics to Announce iPSC-Derived Immunocellular Therapy Strategy at 2026 Cantor Conference
GlobeNewswire USA Overview Fate Therapeutics announced its participation in a fireside chat at the 2026 Annual Cantor Global Healthcare Conference. The company holds a leading position in creating multi-gene-edited iPSC lines and manufac... -
China Approves Satri-Cel, World’s First CAR T-Cell Therapy for Claudin 18.2-Positive Gastric Cancer
PubMed China Overview China's National Medical Products Administration (NMPA) has approved satricabtagene autoleucel (satri-cel), a CAR T-cell therapy for Claudin 18.2-positive, HER2-negative advanced gastric or gastroesophageal junction... -
FibroBiologics Secures U.S. Patent (No. 12,721,866) for Wound Healing with 3D Spheroid Fibroblasts, Targeting Chronic and Acute Wounds
Stock Titan USA Overview FibroBiologics announced the issuance of U.S. Patent No. 12,721,866 on September 1, 2026, for the therapeutic use of fibroblasts in wound healing. This patent covers the topical administration of 3D spheroid fibr... -
ESC Congress 2026 Reveals Breakthrough Gene Therapies for Cardiovascular Disease: AAV8 Reduces LDL-C by 80-90%, siRNA Kylo-11 Achieves 97% Lp(a) Reduction
HCPLive (YouTube) USA Overview Groundbreaking data on multiple gene and molecular therapies for cardiovascular disease were presented at ESC Congress 2026. An AAV8-mediated gene therapy for homozygous familial hypercholesterolemia (HoFH)... -
Ocugen Doses First Patient in Phase 3 Registrational Trial for OCU410 Modifier Gene Therapy for Geographic Atrophy, Following RMAT Designation
GlobeNewswire USA Overview Ocugen has initiated patient dosing in its Phase 3 registrational trial for OCU410, a modifier gene therapy targeting geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). OCU410 rece... -
Fate Therapeutics Initiates Phase 1/2 Trial for Novel Cell Therapy FT839 in Autoimmune Diseases, Expanding Pipeline
TipRanks.com USA Overview Fate Therapeutics has launched a Phase 1/2 dose-escalation and expansion trial for its novel cell therapy candidate, FT839, in patients with autoimmune diseases. This intravenously administered therapy is design...
